Fexofenadine HCl

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes dapsone. Therapeutic category: anti bacterial. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes doxercalciferol. Therapeutic category: vit D. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes enzalutamide. Chemical name: 4-((2-cyanopropan-2-yl)amino) -2-fluoro-N-methylbenzamide. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes epoprostenol. Therapeutic category: prostaglandin. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes ibutilide. Therapeutic category: anti arrhythmic. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes laropiprant. Chemical name: 5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2-dihydrocyclopenta[b]indol-3(4H)-one. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes latanoprost. Therapeutic category: prostaglandin. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes lurasidone. Chemical name: spiro[2H-isoindole-2,1'-piperazin-1'-ium], 4?-(1,2-benzisothiazol-3-yl. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes paricalcitol. Therapeutic category: vit D. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes sofosbuvir. Chemical name: (1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3 methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione). Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes vemurafenib. Chemical name: 4 chloro phenyl boronic acid. Contact us for more information.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the appointment of Sauri Gudlavalleti as its Chief Operating Officer. Sauri will report to the CEO & Managing Director, Krishna Kanumuri and drive the company’s growth as a new generation, science-driven organization.

Sai Life Sciences today announced the release of its 2021 Sustainability Report. 

Sai Life Sciences today commenced recruitment for 100+ scientific positions across medicinal chemistry and biology to bolster the company’s growth plans of achieving scale, scope and speed in its Discovery business. All positions will be based at the company’s Integrated Research & Development campus in Hyderabad, India.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection. 

Sai Life Sciences won the LearnX Live Award, Australia, under the category Best Learning Technology, making it the fifth Learning & Development award for the company in the year.

In a global assessment acknowledged as a gold standard by procurers and suppliers, winning a silver is gratifying. 

Sai Life Sciences, a global CRO & CDMO offering sustainable solutions to pharmaceutical companies through strategic partnerships and integrated drug discovery and development services, has been awarded with ‘Excellent Energy Efficient Unit’ in the general category at CII’s 22nd National Energy Management Awards. 

At its first ever participation in the awards, Sai Life Sciences won the Environmental Supplier award 2021 in the ‘Primary Manufacturing’ category.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that it has become a signatory of the United Nations Global Compact (UNGC), the world’s largest sustainability initiative. 

Sai Life Sciences won the Gold Award in Brandon Hall Group Excellence Awards under the “Best Advance in Learning Technology Implementation” category.

 

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the opening of a new biology facility at its integrated R&D campus in Hyderabad, India. The facility marks an important milestone in the journey of positioning itself as a differentiated player in Discovery Biology.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical category. This is the second consecutive Golden Peacock Award for the company following the Golden Peacock National Quality Award it received in 2020.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO/ CDMO), today announced that its flagship manufacturing facility in Bidar, Karnataka received a 5-star rating for excellence in EHS practices at the 13th edition of the Confederation of Indian Industry’s (CII-SR) EHS Excellence Awards. This is the second consecutive year that the site is achieving this recognition.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced the opening of a new Clean Room block at its cGMP API & Intermediate Manufacturing campus in Bidar, India.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced the addition of Dr. Mahavir Prashad, an acknowledged scientific leader and industry veteran, to its scientific leadership team as Vice President of Early Phase Process Development.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced plans to double its headcount and expand its suite of technical capabilities at its Manchester site, a centre of excellence for API process and analytical development serving an expanding list of global clients.

The company wins two awards at the prestigious 2021 Association for Talent Development - Excellence in Practice (ATD-EIP) awards.

Immediately initiates first phase of recruitment for 100 scientists in API process development and scale-up and will initiate recruitment for 400 positions across Discovery Chemistry, Biology & DMPK in a phased manner over the year

Developed as per the Global Reporting Initiative (GRI) standards and highlights the various sustainable choices embraced by the company

The CRDMO will expand in vitro and in vivo biology services, DMPK and toxicology capabilities.

Following a string of wins over the past year, our Bidar manufacturing facility achieved another success to its credit - this time for excellence in energy management

We have been committed to increasing the adoption of Green Chemistry principles in our process development. Joining the ACS-GCIPR will allow us to interact with large pharma and other CDMOs to further share and develop best practices in Green chemistry and sustainability.

One of India's fastest growing CDMOs goes "beyond the norm" to reinvent itself as a new generation global CDMO.

Our Process Chemistry R&D laboratory at Alderley Park, Manchester is now open for business. Feel free to reach out to us for all your process development needs. Refer this link for information on our new lab.

Sai Life Sciences wins Golden Peocock National Quality award 2020.

Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other viruses.

Since the outbreak of the COVID-19, Sai Life Sciences has been taking several proactive measures to protect its employees and their families, and to minimize the impact on its partners, customers and the community.

As a validation of our commitment to maintaining the highest standards in animal care and compliance with industry and regulatory guidelines, the Sai Life Sciences discovery facility in Pune recently received a renewed accreditation for its laboratory animal care and use program from AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) International.

Over the past few weeks since the outbreak of COVID-19, there’s been a sudden rise in sanitization efforts by various public and private organizations to help arrest the spread of the disease. This, along with efforts of individuals in their own spaces, has created a huge demand for effective alcohol-based sanitizers to aid the sanitization efforts.

Sai Life Sciences, today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an ‘Associate Member’.

Over half a million people in the northern region of Hyderabad will now have access to high-quality eye care in their neighborhood, thanks to the new ‘Sai Life Sciences Eye Care Centre’, which has opened in partnership with the LV Prasad Eye Institute.